414910-03-5

Basic information

• Product Name: 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphen yl)-N-methyl-4-oxo-, (2R)-
• Synonyms: 2-(R)-(4-fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)ethyl]-methylamide;2-(R)-(4-fluoro-2-methylphenyl)-4-oxopiperidine-1-carboxylic acid [1-((R)-3,5-bis-trifluoromethylphenyl)ethyl]methylamide;(2R)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methylamino-carbonyl]-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine;2-(R)-(4-fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid [1-(R)-3,5-bis-(trifluoromethyl-phenyl)-ethyl]-methylamide;(2R)-1-{N-(1-(R)-3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4- fluoro-2-methylphenyl)-4-oxopiperidine
• CAS NO: 414910-03-5
• Molecular Formula: C24H23F7N2O2
• Molecular Weight: 504.448
• Mol File: 414910-03-5.mol

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphen yl)-N-methyl-4-oxo-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphen yl)-N-methyl-4-oxo-, (2R)-(414910-03-5)
• EPA Substance Registry System: 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphen yl)-N-methyl-4-oxo-, (2R)-(414910-03-5)

Safety Data

• Hazardous Substances Data: 414910-03-5(Hazardous Substances Data)

Upstream product

• 629953-69-1 2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine 
• 334477-60-0 [(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl](methyl)amine 
• 414909-99-2 2-(4-fluoro-2-methyl-phenyl)-piperidine-4-one 
• 414910-05-7 (1R)-1-[3,5-bis(trifluoromethyl)phenyl]-N-methylethanaminehydrochloride 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 414910-12-6 (2R)-2-(4-fluoro-2-methylphenyl)-4-piperidinone 
• 17199-29-0 (S)-Mandelic acid 
• 452-63-1 2-Bromo-5-fluorotoluene 
• 579475-69-7 2-(4-fluoro-2-methylphenyl)-4-piperidinone camphor-10-sulfonate 
• 414910-13-7 (2R)-2-(4-fluoro-2-methylphenyl)-4-piperidinone L-(+)-mandelate 
• 414910-00-2 2-(4-fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid benzyl ester 
• 414909-98-1 phenylmethyl 2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate 
• 620-08-6 4-methoxypyridine 

Downstream Products

• 414910-27-3 [14C]-Casopitant 
• 414910-41-1 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(R)-[(4-tert-butoxycarbonyl)-piperazin-1-yl]-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide 
• 414910-42-2 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-[(4-tert-butoxycarbonyl)-piperazin-1-yl]-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide 
• 921765-78-8 C₂₈H₃₁F₇N₄O₂ 
• 928791-15-5 4-(S)-[1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)-ethyl}-N-methylamino-carbonyl]-2-(R)-(4-fluoro-2-methylphenyl)piperidin-4-yl]thiomorpholine 
• 921206-86-2 GSK₆₃₁₈₃₂ 
• 579475-18-6 Orvepitant 
• 1193336-81-0 (2R)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4-methylidene-1-piperidinecarboxamide 
• 1204820-64-3 ethyl 3-[(2R,4R)-1-{[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]carbonyl}-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-3-azabicyclo[3.1.0]hexane-1-carboxylate 
• 1204820-78-9 ethyl (1R,5R)-3-[(2R,4S)-1-{[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]carbonyl}-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-3-azabicyclo[3.1.0]hexane-1-carboxylate 
• 1204820-68-7 methyl 3-[(2R,4R)-1-{[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]carbonyl}-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-3-azabicyclo[4.1.0]heptane-1-carboxylate 
• 1204820-67-6 methyl 3-[(2R,4S)-1-{[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]carbonyl}-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-3-azabicyclo[4.1.0]heptane-1-carboxylate 
• 1204820-77-8 ethyl (1R,5R)-3-[(2R,4R)-1-{[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]carbonyl}-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-3-azabicyclo[3.1.0]hexane-1-carboxylate 
• 1265855-31-9 C₂₇H₃₀F₇N₃O 

Relevant articles and documents

Application of the QbD principles in the development of the casopitant mesylate manufacturing process. Process research studies for the definition of the control strategy of some drug substance-CQAs for stages 2a, 2b, and 2c

Casopitant was identified as a potent NK1 antagonist by GlaxoSmithKline (GSK). It was selected as part of a wide drug discovery programme within GSK for its potential activities on a number of therapeutic targets such as inflammatory bowel dise

Discovery and biological characterization of (2 R,4 S)-1′-Acetyl- N -{(1 R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)- N -methyl-4,4′-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) recepto

A large body of compelling preclinical evidence supports the clinical use of neurokinin (NK) receptor antagonists in a plethora of CNS and non-CNS therapeutic areas. The significant investment made in this area over the past 2 decades culminated with the

ANHYDROUS CRYSTAL FORM OF ORVEPITANT MALEATE

The invention relates to anhydrous crystalline orvepitant maleate (Form 1), pharmaceutical formulations comprising the same, its use in therapy and processes for preparing the same.

THIOMORPHOLINE COMPOUND AND PROCESS FOR PREPARING THE SAME

The present invention discloses a thiomorpholine compound represented by the formula [I]: wherein Ring A represents an optionally substituted benzene ring; Ring B represents an optionally substituted benzene ring; R1 represents hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom; R2 represents hydrogen atom or an optionally substituted alkyl group; and R3a and R3b may be the same or different from each other, and each represent hydrogen atom or an optionally substituted alkyl group, or combined to each other at the both ends thereof to form an alkylene group, and n is an integer of 1 or 2, or a pharmaceutically acceptable salt thereof.

Chemical compounds

Formula (1) wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen, or a C1-4 alkyl group; R4 represents a trifluorometyl group; R5 represents hydrogen, a C1-4 alkyl group or C(0)R6; R6? represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated bytachykinins.

NOVEL PIPERIDINE COMPOUND

The present invention provides a novel piperidine compound of the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R1 represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, etc., or a group of the formula: (a) wherein R11 and R12 are the same or different, and each represents hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, etc., R2 represents hydrogen atom, etc., Z represents oxygen atom or a group represented by -N(R3)-, R3 represents hydrogen atom or an alkyl group, etc., R4 represents hydrogen atom or an alkyl group, etc.,or a pharmaceutically acceptable salt thereof.